RFK Jr. Reportedly Weighs Preventive Services Panel Revamp, Raising Risks for HIV PrEP Drugmakers on July 28, 2025 Advisory Committees drugmakers health disparity HIV prevention Insurance PREP gene preventive services panel public health policy revamp RFK Jr. USPSTF +
WHO to Develop Guidelines for Gilead's Twice-Yearly HIV PrEP Injection (Lenacapavir) on July 14, 2025 Approved Gilead Guidelines HIV prevention Lenacapavir PREP gene twice-yearly injection United States Food and Drug Administration World Health Organization +
Gilead Wins Groundbreaking FDA Approval for Twice-Yearly HIV Prevention Shot on June 20, 2025 Approved Gilead Guidelines HIV prevention Lenacapavir long-acting injectable PREP gene twice-yearly injection United States Food and Drug Administration World Health Organization Yeztugo +
FDA Approves Gilead's Twice-Yearly HIV Prevention Shot on June 19, 2025 Approved Gilead Sciences HIV prevention Lenacapavir PREP gene public health medicine (field) twice-yearly injection United States Food and Drug Administration Yeztugo +
Gilead hops straight to Phase III with once-yearly HIV PrEP shot on March 13, 2025 formulations once-yearly PREP gene Trial Phase +
Gilead Sciences Prepares for Summer 2025 Launch of Long-Acting HIV Prevention Drug Lenacapavir on February 14, 2025 Approved Clinical Trials Gilead Sciences HIV prevention HIV sales Lenacapavir PREP gene PURPOSE studies United States Food and Drug Administration +
Battle for HIV PrEP Market: Gilead's Twice-Yearly Injection Challenges GSK's Apretude on February 07, 2025 Apretude HIV prevention Lenacapavir long-acting injectables PREP gene SmithKline Beecham ViiV Healthcare +